Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state
Open Access
- 1 December 2016
- journal article
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 9, 98-105
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development (15AeK0109050s0302)
This publication has 20 references indexed in Scilit:
- Long-Term Prognosis of Patients with Infantile-Onset Pompe Disease Diagnosed by Newborn Screening and Treated since BirthThe Journal of Pediatrics, 2015
- A large‐scale nationwide newborn screening program for pompe disease in Taiwan: Towards effective diagnosis and treatmentAmerican Journal of Medical Genetics Part A, 2013
- How to describe the clinical spectrum in Pompe disease?American Journal of Medical Genetics Part A, 2013
- CRIM-Negative Pompe Disease Patients with Satisfactory Clinical Outcomes on Enzyme Replacement Therapy2012
- The emerging phenotype of long-term survivors with infantile Pompe diseaseGenetics in Medicine, 2012
- Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infantsMolecular Genetics and Metabolism, 2010
- Pompe's diseaseThe Lancet, 2008
- Recombinant human acid α-glucosidaseNeurology, 2007
- Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe diseaseLaboratory Investigation, 2006
- Pompe disease in infants and childrenThe Journal of Pediatrics, 2004